Daniel Silva Barbosa

Learn More
BACKGROUND Renal failure (RF) is reported to occur in 11-49% of the patients with decompensated end-stage liver disease (ESLD) and has been associated with increased mortality, particularly in the occurrence of hepatorenal syndrome (HRS) type 1. AIMS To evaluate the frequency and outcome of RF in patients admitted to the hospital due to decompensated ESLD(More)
CONTEXT Treatment of hepatorenal syndrome type 1 (HRS-1) with splanchnic vasoconstrictors and high-dose albumin has been associated with reversal of renal failure in approximately 60% to 80% of the cases in pilot or uncontrolled studies. OBJECTIVE To evaluate the results of treatment of HRS-1 with terlipressin and high-dose albumin. METHODS All patients(More)
  • 1